North America Veterinary Soft Chew Development and Contract Manufacturing Market Size, Trends & Growth Opportunity By Commercial Service, By Product Type, By Formulation Platform, By Customer Type, By Region and Forecast Till 2030

Report ID : AMR1006271 | Industries : Healthcare | Published On :October 2026 | Page Count : 218

Request Sample
Ask for Customization

The North America veterinary soft chew development and contract manufacturing market covers the outsourced services through which brand owners turn a soft chew concept into a commercial product, from formulation and palatability work through analytical support, scale-up and finished-product manufacturing.

A soft chew is a moist, pliable oral dosage form that carries nutritional, nutraceutical or pharmaceutical actives in a palatable matrix, and the report treats it here strictly as a product category and market segment.

A contract development and manufacturing organisation, or CDMO, is a company that develops and produces a client's formulation under contract, and the market is defined by that service relationship rather than by the chews themselves.

The scope is North America as a single region and covers dogs, cats, horses and other companion animals. It excludes in-house manufacturing that never enters a contract relationship, and it excludes tablets, capsules, liquids and powders except where they appear as alternative dosage forms.

The report organises demand across nine segmentation dimensions: commercial service, soft chew product type, formulation platform, active ingredient category, functional health application, target animal, customer type, customer engagement model and production scale.

The report describes veterinary and nutraceutical categories as market segments only. It makes no clinical, safety or efficacy claim about any product, ingredient or company, and it names regulatory and quality frameworks only as market-access categories.

Soft chews sit between treats and tablets in how owners perceive them. They are given daily as supplements or intermittently as medicated products, and that dual position is why the market spans both nutraceutical and pharmaceutical customers under a single service definition.

North America is treated as one region because the soft chew supply base, the large pet supplement brands and the animal-health companies operate across the whole continent, and a regional supplier serving only one country is the exception rather than the norm.

Market Size & Growth Forecast (2026 to 2030)

The North America veterinary soft chew development and contract manufacturing market is estimated at approximately USD 100 Million in 2025 and is projected to reach approximately USD 147 Million by 2030, expanding at a compound annual growth rate of roughly 8.0 percent.

The estimate covers contract development fees and contract manufacturing revenue for soft chews sold into companion animal and equine channels in North America, and it excludes the retail value of finished chews that are manufactured in-house by brand owners.

Commercial contract manufacturing forms the largest commercial service category by revenue, while custom formulation development and turnkey development-to-commercialisation services together form the fastest-growing service categories.

Veterinary nutraceutical and wellness soft chews account for the largest product type category, and medicated and pharmaceutical soft chews form the fastest-growing product type category as brand owners move established dosage forms into chewable formats.

Conventional starch-based soft chews remain the largest formulation platform by volume, while starch-free and low-temperature processed platforms form the fastest-growing platform category tied to heat-sensitive and high-active formulations.

Pet supplement brands account for the largest customer type category, and emerging and digitally native pet-health brands form the fastest-growing customer type category.

The forecast assumes continued pet humanisation and chewable format adoption across North America, and a sustained shift toward in-house manufacturing among large brand owners would move the trajectory.

MetricValue
Market Size (2025)Approximately USD 100 Million
Forecast Size (2030)Approximately USD 147 Million
CAGR (2025-2030)Approximately 8.0%
Base Year2025
Forecast Period2026-2030 (5-year)
Scope NoteSoft chew development and contract manufacturing services for companion animals and horses in North America; excludes in-house manufacturing and other dosage forms
Largest Service CategoryCommercial contract manufacturing
Fastest-Growing Service CategoryCustom formulation development and turnkey services
Largest Product Type CategoryVeterinary nutraceutical and wellness soft chews
Fastest-Growing Product TypeMedicated and pharmaceutical soft chews
Largest Formulation PlatformConventional starch-based soft chews
Fastest-Growing PlatformStarch-free soft chews
Largest Customer TypePet supplement brands
Geographic CoverageNorth America as a single region

 

Market Drivers

Continued pet humanisation across North America, with owners extending human wellness habits to dogs, cats and horses and sustaining demand for functional chewable formats.

Owner preference for palatable chewable dosage forms over tablets, capsules and powders, which keeps soft chews central to supplement and veterinary product line extensions.

Brand owners moving from other dosage forms into soft chews and seeking development, analytical and manufacturing capability from a single outsourced partner.

Growth of digitally native pet-health brands and retail private-label programmes that rely on contract partners rather than owned manufacturing assets.

Rising interest in pharmaceutical-grade soft chews, which widens the range of actives and quality systems that contract partners must support.

Pharmaceutical-grade ambitions are a further driver. As more customers want medicated and prescription-adjacent chewable formats, contract partners with quality documentation and analytical capability become scarcer, and the value of those capabilities rises accordingly.

MARKET SHIFT

The buyers adding the most demand are brands without manufacturing assets, which means outsourced partners increasingly sell a pathway of development, analytical and production services rather than capacity alone.

 

Market Restraints

Technical difficulty of incorporating high active loads and heat-sensitive ingredients while maintaining moisture control, texture and shelf stability.

Capacity constraints and minimum order quantities that limit access for emerging brands and lengthen development-to-commercial timelines.

Ingredient sourcing volatility and supply-chain vulnerability affecting actives, palatants and excipients.

Insourcing and alternative dosage-form risk, together with regulatory and labelling complexity across supplement and pharmaceutical product categories.

Customer consolidation and CDMO consolidation, which change the number of independent partners available to mid-sized buyers.

Pricing pressure from private-label programmes and large retailers adds a commercial restraint, since it compresses the margin a supplier can earn on high-volume standard formulations.

PROCUREMENT INSIGHT

Because scale-up failures and long development timelines sit among the most cited customer pain points, buyers weight demonstrated development-to-commercial continuity heavily when qualifying a partner, which favours suppliers that retain the same team from pilot batches to commercial runs.

 

Market Opportunities

Considerable untapped opportunity in pharmaceutical-grade soft chews and in complex or high-active-load formulations.

Starch-free and low-temperature platforms for heat-sensitive actives.

Faster development and scale-up pathways, and low minimum order quantity offerings for emerging brands.

Second-source manufacturing for brands seeking supply continuity and premium veterinary-exclusive products for underserved customer segments.

Commercial Services and Engagement Models

Buyers weigh development and manufacturing services as a connected pathway, since the report tracks thirteen commercial service categories from concept development and palatability work through stability testing, technology transfer, commercial manufacturing, packaging and turnkey delivery.

Six customer engagement models run across those services, from customer-owned formulation and technology transfer to jointly developed proprietary formulations, CDMO-developed custom formulations, modified base formulations, private-label programmes and full turnkey delivery, and four production scales run from pilot batches to high-volume commercial manufacturing.

The services most often bundled are formulation, palatability and stability work, which buyers contract together because each depends on decisions made in the others. Technology transfer and scale-up are the stage at which programmes are most exposed to delay, so partners that can demonstrate continuity across that handoff are valued.

For a brand owner the practical question is where the pathway starts. Those holding a formulation begin at technology transfer and buy only production, while those holding only a concept buy the entire sequence, and the report's engagement model dimension is organised around exactly that distinction.

Product Types and Formulation Platforms

The choice of formulation platforms and product types shapes what a brand owner can build, with seven product types running from nutritional and wellness chews to medicated and pharmaceutical, pill-hiding, veterinary-exclusive and private-label chews, carried on starch-based, starch-free, low-moisture, cold-processed, extruded, molded and proprietary chew-matrix platforms.

Platform choice also governs which suppliers a buyer can consider at all. A starch-free or low-temperature requirement removes any supplier running only conventional starch-based lines, and a pharmaceutical-grade requirement removes those without the documentation to support it.

Among product types, nutritional and wellness chews are the entry format for many customers, veterinary nutraceutical chews carry the largest revenue, and medicated and pharmaceutical chews are the fastest growing, so the product mix of the market is shifting gradually toward higher-specification formats.

Active Ingredients, Health Applications and Target Animals

Demand is framed by active ingredients and health application categories, with eleven ingredient categories from vitamins, minerals and joint actives to probiotics, omega fatty acids, botanicals, enzymes and pharmaceutical actives, fourteen functional health application categories and four target animal groups covering dogs, cats, horses and other companion animals.

The ingredient dimension matters commercially because it governs technical difficulty. Vitamins and minerals are handled readily on conventional lines, while probiotics, enzymes and peptides call for protective processing, and pharmaceutical actives call for documentation that many suppliers do not hold.

Application categories are those used in the market, such as hip, joint and mobility, digestive and gut health, calming support, skin and coat and general wellness, and the report makes no statement about the effect of any ingredient or application on an animal.

Customer Types and Outsourcing Behaviour

Outsourcing decisions differ by customer type and outsourcing behaviour, with eight customer types from animal-health pharmaceutical companies to digitally native pet-health brands, five outsourcing behaviours from fully outsourced programmes to dual-source strategies, and a seventeen-point set of partner selection criteria.

Customer scale cuts across type. Large multinational animal-health companies, mid-sized brands, high-growth specialists, start-ups and retail programmes all appear in the report, and each weighs minimum order quantities, lead times and quality systems differently.

Demand opportunities identified include customers moving from other dosage forms into soft chews, brands seeking a second manufacturing source and brands needing capacity expansion, each of which is a distinct reason to open a contract relationship.

Veterinary Soft Chew Development and Contract Manufacturing Market, By Region

This report covers North America as a single region and does not publish a country or sub-regional split.

North American demand is concentrated where pet supplement brands, animal-health companies and private-label retailers cluster, and the soft chew supplier base is likewise concentrated in North American production sites that serve the whole region.

The report's regional view is therefore a regional competitive footprint view, covering which suppliers operate North American soft chew development and manufacturing capability, how that capability serves different customer types, and where geographic whitespace remains for new entrants.

REGIONAL OPPORTUNITY

A single North American footprint means a supplier's reach is judged by capability breadth and capacity rather than by country coverage, so buyers compare partners on species coverage, platform range and scale rather than on location.

 

Leading Companies

Vetio Animal Health, Vets Plus, Inc., CompletePet, Precision Science, Garmon Corp., Pet Tech Labs, Big Creek Foods, Bimini Pet Health, SynergyLabs and PetIQ are covered in the full report, listed in no order of ranking or preference. An introduction to the supplier landscape by company type is available in leading veterinary soft chew contract manufacturers.

The profiles in the report cover each company's overview, North American footprint, soft chew development and manufacturing capabilities, formulation technology, species focus, quality systems, regulatory capabilities and distribution approach.

Beyond This Page

The full report extends well past the segmentation summarised here and into the commercial detail that shapes how soft chew programmes are actually won and retained.

Buyer intelligence maps customer segmentation, customer scale, outsourcing behaviour, selection criteria and contracting dynamics in full, along with a catalogue of customer pain points and unmet needs.

Competitive benchmarking compares suppliers across development capabilities, formulation technologies, species coverage, pharmaceutical and nutraceutical capabilities and further metrics, without disclosing that positioning data here.

The commercial economics section covers development economics, manufacturing economics, pricing models and margin analysis, and the go-to-market section covers account prioritisation, partnership routes and cross-selling of services.

Frequently Asked Questions

The market is estimated at approximately USD 100 Million in 2025 and is projected to reach approximately USD 147 Million by 2030, expanding at a compound annual growth rate of roughly 8.0 percent.

It covers outsourced services such as custom formulation, palatability development, prototype and pilot batches, analytical and stability work, technology transfer, scale-up, commercial manufacturing, packaging and turnkey delivery.

A contract development and manufacturing organisation that develops and produces a client's soft chew formulation under contract. The report describes the category strictly as a market segment.

Commercial contract manufacturing is the largest service category, while custom formulation development and turnkey services are the fastest growing. Medicated and pharmaceutical soft chews form the fastest-growing product type category.

Customers include animal-health pharmaceutical companies, veterinary nutraceutical companies, pet supplement brands, established pet-care companies, consumer-health entrants, private-label retailers and digitally native pet-health brands.

The report covers dogs, cats, horses and other companion animals.

North America as a single region. No country or sub-regional split is published.

It adds buyer intelligence, competitive and technology benchmarking, company profiles, commercial economics and go-to-market analysis.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. North America Veterinary Soft Chew Development and Contract Manufacturing Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Continued Pet Humanisation in North America, with Owners Extending Human Wellness Habits to Dogs, Cats and Horses and Sustaining Demand for Functional Chewable Formats.

3.3.2. Owner Preference for Palatable Chewable Dosage Forms Over Tablets, Capsules and Powders, Which Keeps Soft Chews Central to Supplement and Veterinary Product Line Extensions.

3.3.3. Brand Owners Moving from Other Dosage Forms into Soft Chews and Seeking Development, Analytical and Manufacturing Capability from a Single Outsourced Partner.

3.3.4. Growth of Digitally Native Pet-Health Brands and Retail Private-Label Programmes That Rely on Contract Partners Rather Than Owned Manufacturing Assets.

3.4. Restraints

3.4.1. Technical Difficulty of Incorporating High Active Loads and Heat-Sensitive Ingredients While Maintaining Moisture Control, Texture and Shelf Stability.

3.4.2. Capacity Constraints and Minimum Order Quantities That Limit Access for Emerging Brands and Lengthen Development-to-Commercial Timelines.

3.4.3. Ingredient Sourcing Volatility and Supply-Chain Vulnerability Affecting Actives, Palatants and Excipients.

3.4.4. Insourcing and Alternative Dosage-Form Risk, Together with Regulatory and Labelling Complexity Across Supplement and Pharmaceutical Product Categories.

3.5. Opportunities

3.5.1. Considerable Untapped Opportunity in Pharmaceutical-Grade Soft Chews and Complex or High-Active-Load Formulations.

3.5.2. Starch-Free and Low-Temperature Platforms for Heat-Sensitive Actives.

3.5.3. Faster Development and Scale-Up Pathways and Low Minimum Order Quantity Offerings for Emerging Brands.

3.5.4. Second-Source Manufacturing and Premium Veterinary-Exclusive Products for Underserved Customer Segments.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Commercial Service

4.1. Concept and Product Development

4.2. Custom Formulation Development

4.3. Formulation Optimisation and Reformulation

4.4. Palatability Development

4.5. Prototype and Pilot Batches

4.6. Analytical Method Development

4.7. Stability Testing

4.8. Technology Transfer

4.9. Process Development and Scale-Up

4.10. Commercial Contract Manufacturing

4.11. Packaging and Finished-Product Services

4.12. Regulatory and Technical Support

4.13. Turnkey and End-to-End CDMO Services

5. Soft Chew Product Type

5.1. Nutritional and Wellness Soft Chews

5.2. Veterinary Nutraceutical Soft Chews

5.3. Functional Soft Chews

5.4. Medicated and Pharmaceutical Soft Chews

5.5. Pill-Hiding and Administration Chews

5.6. Veterinary-Exclusive Formulations

5.7. Private-Label and White-Label Soft Chews

6. Formulation Platform

6.1. Conventional Starch-Based Soft Chews

6.2. Starch-Free Soft Chews

6.3. Low-Moisture Soft Chews

6.4. Cold and Low-Temperature Processed Chews

6.5. Extruded Soft Chews

6.6. Molded and Formed Chews

6.7. Proprietary Chew-Matrix Technologies

7. Active Ingredient Category

7.1. Vitamins and Minerals

7.2. Glucosamine, Chondroitin and MSM

7.3. Probiotics, Prebiotics and Postbiotics

7.4. Omega Fatty Acids

7.5. Botanicals and Plant Extracts

7.6. Amino Acids

7.7. Enzymes

7.8. Antioxidants

7.9. Functional Proteins and Peptides

7.10. Pharmaceutical Actives

7.11. Multi-Active Formulations

8. Functional Health Application

8.1. Hip, Joint and Mobility

8.2. Digestive and Gut Health

8.3. Calming, Stress and Behavioural Support

8.4. Skin and Coat

8.5. Immune Support

8.6. Dental and Oral Health

8.7. Cognitive Support

8.8. Cardiovascular Support

8.9. Urinary Health

8.10. Liver Support

8.11. Weight and Metabolic Management

8.12. Healthy Aging and Senior-Pet Support

8.13. General Wellness and Multivitamin

8.14. Condition-Specific Veterinary Applications

9. Target Animal

9.1. Dogs

9.2. Cats

9.3. Horses

9.4. Other Companion Animals

10. Customer Type

10.1. Animal-Health Pharmaceutical Companies

10.2. Veterinary Nutraceutical Companies

10.3. Pet Supplement Brands

10.4. Established Pet-Care Companies

10.5. Consumer-Health Companies Entering Pet Health

10.6. Retail and Private-Label Organisations

10.7. Veterinary-Exclusive Brands

10.8. Emerging and Digitally Native Pet-Health Brands

11. Customer Engagement Model

11.1. Customer-Owned Formulation and Technology Transfer

11.2. Jointly Developed Proprietary Formulation

11.3. CDMO-Developed Custom Formulation

11.4. Modified Base Formulation

11.5. Private-Label and White-Label Formulation

11.6. Full Turnkey Development-to-Commercialisation

12. Production Scale

12.1. Development and Pilot Scale

12.2. Small Commercial Batches

12.3. Mid-Volume Production

12.4. High-Volume Commercial Manufacturing

13. Customer and Commercial Buyer Intelligence

13.1. Customer Segmentation

13.1.1. Veterinary Pharmaceutical Companies

13.1.2. Animal-Health Companies

13.1.3. Pet Nutraceutical Brands

13.1.4. Pet Supplement Companies

13.1.5. Veterinary-Exclusive Brands

13.1.6. Private-Label Retailers

13.1.7. E-Commerce and Digitally Native Pet-Health Brands

13.1.8. Emerging Pet-Wellness Companies

13.2. Customer Scale Classification

13.2.1. Large Multinational Animal Health Companies

13.2.2. Mid-Sized Established Brands

13.2.3. High-Growth Specialist Pet-Health Brands

13.2.4. Emerging and Start-Up Brands

13.2.5. Retail and Private-Label Programmes

13.3. Soft Chew Outsourcing Behaviour

13.3.1. Fully Outsourced Development and Manufacturing

13.3.2. Formulation Outsourced and Manufacturing Retained

13.3.3. Manufacturing Outsourced Using Customer Formulation

13.3.4. Dual Source and Multi-CDMO Strategies

13.3.5. In-House Versus Outsourced Manufacturing Decision Factors

13.4. CDMO Selection Criteria

13.4.1. Animal-Health Specialisation

13.4.2. Formulation Capabilities

13.4.3. Soft-Chew Manufacturing Experience

13.4.4. Palatability Expertise

13.4.5. Ability to Handle Complex and High-Active Formulations

13.4.6. Stability Performance

13.4.7. Regulatory Track Record

13.4.8. Quality Systems

13.4.9. Manufacturing Scalability

13.4.10. Minimum Order Quantities

13.4.11. Production Capacity

13.4.12. Lead Times

13.4.13. Ingredient Sourcing

13.4.14. Packaging Capabilities

13.4.15. IP Protection

13.4.16. Commercial Pricing

13.4.17. Supply Continuity

13.5. Buying and Contracting Dynamics

13.5.1. Decision-Maker Mapping

13.5.2. R&D and Formulation Influence

13.5.3. Procurement Influence

13.5.4. Commercial and Business-Development Influence

13.5.5. Quality and Regulatory Approval

13.5.6. Typical Vendor Qualification Process

13.5.7. RFP and RFQ Dynamics

13.5.8. Development-to-Commercial Contract Pathway

13.5.9. Switching Barriers

13.5.10. Customer Retention Factors

13.5.11. Typical Contract Duration

13.5.12. Annual Volume Commitment Patterns

13.6. Demand and Opportunity Mapping

13.6.1. High-Growth Customer Categories

13.6.2. Soft-Chew Pipeline Development Activity

13.6.3. Customers Moving from Other Dosage Forms into Soft Chews

13.6.4. Brands Seeking Second-Source Manufacturing

13.6.5. Brands Requiring Capacity Expansion

13.6.6. Private-Label Opportunities

13.6.7. High-Value Pharmaceutical Versus Supplement Opportunities

13.7. Customer Entity Intelligence and Commercial Opportunity Database

13.7.1. Named Animal-Health Companies Outsourcing Soft-Chew Development and Manufacturing

13.7.2. Named Pet Supplement and Nutraceutical Brands

13.7.3. Veterinary Pharmaceutical Prospects

13.7.4. Private Label and Retail Prospects

13.7.5. Emerging Pet-Health Companies

13.7.6. Company Name

13.7.7. Website

13.7.8. Headquarters

13.7.9. Operating Geography

13.7.10. Company Size and Estimated Revenue

13.7.11. Product Portfolio

13.7.12. Existing Soft-Chew Presence

13.7.13. Current Dosage Formats

13.7.14. Likely Outsourcing Requirements

13.7.15. Estimated Commercial and Manufacturing Potential

13.7.16. Relevant Decision-Maker Function

13.7.17. Commercial, Procurement and R&D Contact Information Where Available

13.7.18. Account Attractiveness Score

13.7.19. Strategic-Fit Ranking for Vetio

13.7.20. High, Medium and Emerging Opportunity Classification

13.8. Customer Pain Points and Unmet Needs

13.8.1. Difficulty Incorporating High Active Loads

13.8.2. Heat-Sensitive Ingredient Degradation

13.8.3. Moisture and Stability Challenges

13.8.4. Poor Texture Over Shelf Life

13.8.5. Palatability Inconsistencies

13.8.6. Ingredient Compatibility Issues

13.8.7. Batch-to-Batch Consistency

13.8.8. Development-to-Commercial Scale-Up Failures

13.8.9. Long CDMO Development Timelines

13.8.10. High Minimum Order Quantities

13.8.11. Manufacturing Capacity Constraints

13.8.12. Ingredient Sourcing Volatility

13.8.13. Regulatory and Labelling Complexity

13.8.14. Packaging and Shelf-Life Issues

13.8.15. Limited Pharmaceutical-Grade Soft-Chew Capabilities

13.8.16. Need for Integrated Development, Analytical and Manufacturing Partners

13.8.17. Need for Stronger IP Protection and Proprietary Formulation Options

14. North America Market Analysis and Forecast (2026–2030)

14.1. Introduction

14.2. Market Share Analysis

14.3. Market Size and Forecast

14.4. Market Size and Forecast, By Geography

15. Competition Analysis

15.1. Market Positioning Overview

15.1.1. Animal-Health-Specialist CDMOs Versus General Nutraceutical Manufacturers

15.1.2. Formulation-Led Versus Manufacturing-Led Competitors

15.1.3. Pharmaceutical-Grade Versus Supplement-Focused Capabilities

15.1.4. Custom Formulation Versus Private-Label Positioning

15.1.5. Small-Batch Versus High-Volume Positioning

15.1.6. Full-Service Versus Manufacturing-Only Business Models

15.2. Competitive Benchmarking Metrics

15.2.1. Estimated North American Soft-Chew Manufacturing Position

15.2.2. Soft-Chew Manufacturing Capacity

15.2.3. Development Capabilities

15.2.4. Formulation Technologies

15.2.5. Species Coverage

15.2.6. Pharmaceutical Capabilities

15.2.7. Nutraceutical Capabilities

15.2.8. Palatability Capabilities

15.2.9. Stability and Analytical Support

15.2.10. Manufacturing Technology

15.2.11. Minimum Order Requirements

15.2.12. Commercial-Scale Capacity

15.2.13. Lead Times

15.2.14. Quality Certifications

15.2.15. Regulatory Capabilities

15.2.16. Packaging Services

15.2.17. Customer Positioning

15.2.18. Geographic Reach

15.3. Strategic Moves

15.3.1. Capacity Expansion

15.3.2. New Production Lines

15.3.3. Facility Investments

15.3.4. Technology Launches

15.3.5. New Formulations

15.3.6. Partnerships

15.3.7. Acquisitions

15.3.8. Customer and Market Expansion

15.4. Competitive Mapping & Gaps

15.4.1. Pharmaceutical-Grade Soft-Chew Opportunities

15.4.2. Complex Formulation Opportunities

15.4.3. High-Active-Load Formulations

15.4.4. Heat-Sensitive Actives

15.4.5. Starch-Free Platforms

15.4.6. Faster Development and Scale-Up

15.4.7. Low-MOQ Opportunities

15.4.8. Second-Source Manufacturing

15.4.9. Premium Veterinary-Exclusive Products

15.4.10. Underserved Customer Segments

16. Company Profiles

16.1. Vetio Animal Health

16.1.1. Company Overview

16.1.2. Headquarters, Ownership and Workforce

16.1.3. North American Footprint

16.1.4. Soft-Chew Development and Manufacturing Capabilities

16.1.5. Formulation Technology

16.1.6. Animal and Species Focus

16.1.7. Functional and Application Coverage

16.1.8. Target Customer Segments

16.1.9. CDMO and Private-Label Business Model

16.1.10. Production Capabilities and Scale

16.1.11. Quality Systems and Certifications

16.1.12. Regulatory Capabilities

16.1.13. Distribution and Go-to-Market

16.1.14. R&D and Innovation

16.1.15. Partnerships

16.1.16. Capacity Investments

16.1.17. Recent Developments

16.1.18. SWOT Snapshot

16.2. Vets Plus, Inc.

16.2.1. Company Overview

16.2.2. Headquarters, Ownership and Workforce

16.2.3. North American Footprint

16.2.4. Soft-Chew Development and Manufacturing Capabilities

16.2.5. Formulation Technology

16.2.6. Animal and Species Focus

16.2.7. Functional and Application Coverage

16.2.8. Target Customer Segments

16.2.9. CDMO and Private-Label Business Model

16.2.10. Production Capabilities and Scale

16.2.11. Quality Systems and Certifications

16.2.12. Regulatory Capabilities

16.2.13. Distribution and Go-to-Market

16.2.14. R&D and Innovation

16.2.15. Partnerships

16.2.16. Capacity Investments

16.2.17. Recent Developments

16.2.18. SWOT Snapshot

16.3. CompletePet

16.3.1. Company Overview

16.3.2. Headquarters, Ownership and Workforce

16.3.3. North American Footprint

16.3.4. Soft-Chew Development and Manufacturing Capabilities

16.3.5. Formulation Technology

16.3.6. Animal and Species Focus

16.3.7. Functional and Application Coverage

16.3.8. Target Customer Segments

16.3.9. CDMO and Private-Label Business Model

16.3.10. Production Capabilities and Scale

16.3.11. Quality Systems and Certifications

16.3.12. Regulatory Capabilities

16.3.13. Distribution and Go-to-Market

16.3.14. R&D and Innovation

16.3.15. Partnerships

16.3.16. Capacity Investments

16.3.17. Recent Developments

16.3.18. SWOT Snapshot

16.4. Precision Science

16.4.1. Company Overview

16.4.2. Headquarters, Ownership and Workforce

16.4.3. North American Footprint

16.4.4. Soft-Chew Development and Manufacturing Capabilities

16.4.5. Formulation Technology

16.4.6. Animal and Species Focus

16.4.7. Functional and Application Coverage

16.4.8. Target Customer Segments

16.4.9. CDMO and Private-Label Business Model

16.4.10. Production Capabilities and Scale

16.4.11. Quality Systems and Certifications

16.4.12. Regulatory Capabilities

16.4.13. Distribution and Go-to-Market

16.4.14. R&D and Innovation

16.4.15. Partnerships

16.4.16. Capacity Investments

16.4.17. Recent Developments

16.4.18. SWOT Snapshot

16.5. Garmon Corp.

16.5.1. Company Overview

16.5.2. Headquarters, Ownership and Workforce

16.5.3. North American Footprint

16.5.4. Soft-Chew Development and Manufacturing Capabilities

16.5.5. Formulation Technology

16.5.6. Animal and Species Focus

16.5.7. Functional and Application Coverage

16.5.8. Target Customer Segments

16.5.9. CDMO and Private-Label Business Model

16.5.10. Production Capabilities and Scale

16.5.11. Quality Systems and Certifications

16.5.12. Regulatory Capabilities

16.5.13. Distribution and Go-to-Market

16.5.14. R&D and Innovation

16.5.15. Partnerships

16.5.16. Capacity Investments

16.5.17. Recent Developments

16.5.18. SWOT Snapshot

16.6. Pet Tech Labs

16.6.1. Company Overview

16.6.2. Headquarters, Ownership and Workforce

16.6.3. North American Footprint

16.6.4. Soft-Chew Development and Manufacturing Capabilities

16.6.5. Formulation Technology

16.6.6. Animal and Species Focus

16.6.7. Functional and Application Coverage

16.6.8. Target Customer Segments

16.6.9. CDMO and Private-Label Business Model

16.6.10. Production Capabilities and Scale

16.6.11. Quality Systems and Certifications

16.6.12. Regulatory Capabilities

16.6.13. Distribution and Go-to-Market

16.6.14. R&D and Innovation

16.6.15. Partnerships

16.6.16. Capacity Investments

16.6.17. Recent Developments

16.6.18. SWOT Snapshot

16.7. Big Creek Foods

16.7.1. Company Overview

16.7.2. Headquarters, Ownership and Workforce

16.7.3. North American Footprint

16.7.4. Soft-Chew Development and Manufacturing Capabilities

16.7.5. Formulation Technology

16.7.6. Animal and Species Focus

16.7.7. Functional and Application Coverage

16.7.8. Target Customer Segments

16.7.9. CDMO and Private-Label Business Model

16.7.10. Production Capabilities and Scale

16.7.11. Quality Systems and Certifications

16.7.12. Regulatory Capabilities

16.7.13. Distribution and Go-to-Market

16.7.14. R&D and Innovation

16.7.15. Partnerships

16.7.16. Capacity Investments

16.7.17. Recent Developments

16.7.18. SWOT Snapshot

16.8. Bimini Pet Health

16.8.1. Company Overview

16.8.2. Headquarters, Ownership and Workforce

16.8.3. North American Footprint

16.8.4. Soft-Chew Development and Manufacturing Capabilities

16.8.5. Formulation Technology

16.8.6. Animal and Species Focus

16.8.7. Functional and Application Coverage

16.8.8. Target Customer Segments

16.8.9. CDMO and Private-Label Business Model

16.8.10. Production Capabilities and Scale

16.8.11. Quality Systems and Certifications

16.8.12. Regulatory Capabilities

16.8.13. Distribution and Go-to-Market

16.8.14. R&D and Innovation

16.8.15. Partnerships

16.8.16. Capacity Investments

16.8.17. Recent Developments

16.8.18. SWOT Snapshot

16.9. SynergyLabs

16.9.1. Company Overview

16.9.2. Headquarters, Ownership and Workforce

16.9.3. North American Footprint

16.9.4. Soft-Chew Development and Manufacturing Capabilities

16.9.5. Formulation Technology

16.9.6. Animal and Species Focus

16.9.7. Functional and Application Coverage

16.9.8. Target Customer Segments

16.9.9. CDMO and Private-Label Business Model

16.9.10. Production Capabilities and Scale

16.9.11. Quality Systems and Certifications

16.9.12. Regulatory Capabilities

16.9.13. Distribution and Go-to-Market

16.9.14. R&D and Innovation

16.9.15. Partnerships

16.9.16. Capacity Investments

16.9.17. Recent Developments

16.9.18. SWOT Snapshot

16.10. PetIQ

16.10.1. Company Overview

16.10.2. Headquarters, Ownership and Workforce

16.10.3. North American Footprint

16.10.4. Soft-Chew Development and Manufacturing Capabilities

16.10.5. Formulation Technology

16.10.6. Animal and Species Focus

16.10.7. Functional and Application Coverage

16.10.8. Target Customer Segments

16.10.9. CDMO and Private-Label Business Model

16.10.10. Production Capabilities and Scale

16.10.11. Quality Systems and Certifications

16.10.12. Regulatory Capabilities

16.10.13. Distribution and Go-to-Market

16.10.14. R&D and Innovation

16.10.15. Partnerships

16.10.16. Capacity Investments

16.10.17. Recent Developments

16.10.18. SWOT Snapshot

Frequently Asked Questions

The market is estimated at approximately USD 100 Million in 2025 and is projected to reach approximately USD 147 Million by 2030, expanding at a compound annual growth rate of roughly 8.0 percent.

It covers outsourced services such as custom formulation, palatability development, prototype and pilot batches, analytical and stability work, technology transfer, scale-up, commercial manufacturing, packaging and turnkey delivery.

A contract development and manufacturing organisation that develops and produces a client's soft chew formulation under contract. The report describes the category strictly as a market segment.

Commercial contract manufacturing is the largest service category, while custom formulation development and turnkey services are the fastest growing. Medicated and pharmaceutical soft chews form the fastest-growing product type category.

Customers include animal-health pharmaceutical companies, veterinary nutraceutical companies, pet supplement brands, established pet-care companies, consumer-health entrants, private-label retailers and digitally native pet-health brands.

The report covers dogs, cats, horses and other companion animals.

North America as a single region. No country or sub-regional split is published.

It adds buyer intelligence, competitive and technology benchmarking, company profiles, commercial economics and go-to-market analysis.

Inquire Before Buying Request Free Sample Ask For Discount

Parent category anchor.

No published dataset isolates North American veterinary soft chew development and contract manufacturing, so the estimate is derived top-down from the published pet supplements category. Industry estimates place the global pet supplements category at roughly USD 2.7 to 3.1 Billion in 2025, with North America accounting for roughly 36 to 43 percent of that value and chewable forms accounting for roughly 44 percent of form-level revenue.

Derivation to a contract services value.

Applying those published ratios gives a North American chewable supplement category of about USD 0.5 Billion at retail value. This analysis assumes soft chews make up about 70 percent of chewables, that manufacturer-level revenue is about 40 percent of retail value, that medicated and pharmaceutical soft chews add about 25 percent on top of supplements, and that about half of manufacturing is outsourced, with development fees adding about 10 percent. These ratios are analyst assumptions, not published figures, and together they produce approximately USD 100 Million for 2025.

Growth basis.

Published growth rates for the pet supplements category range from roughly 4.7 to 8.7 percent, and published commentary identifies soft chews as among the fastest-growing forms. The forecast applies a compound annual growth rate of 8.0 percent, near the upper end of the published range, reflecting outsourcing growth from digitally native brands and the movement of established dosage forms into chewable formats, giving approximately USD 147 Million by 2030.

Forecast basis and its principal sensitivity.

The principal sensitivity is the outsourced share of manufacturing: each five-point change in that assumption moves the 2025 estimate by roughly USD 10 Million. Segment and customer leaders are analyst judgements informed by the segmentation structure and the customer pain points documented in the report, not published shares.

Frequently Asked Questions

The market is estimated at approximately USD 100 Million in 2025 and is projected to reach approximately USD 147 Million by 2030, expanding at a compound annual growth rate of roughly 8.0 percent.

It covers outsourced services such as custom formulation, palatability development, prototype and pilot batches, analytical and stability work, technology transfer, scale-up, commercial manufacturing, packaging and turnkey delivery.

A contract development and manufacturing organisation that develops and produces a client's soft chew formulation under contract. The report describes the category strictly as a market segment.

Commercial contract manufacturing is the largest service category, while custom formulation development and turnkey services are the fastest growing. Medicated and pharmaceutical soft chews form the fastest-growing product type category.

Customers include animal-health pharmaceutical companies, veterinary nutraceutical companies, pet supplement brands, established pet-care companies, consumer-health entrants, private-label retailers and digitally native pet-health brands.

The report covers dogs, cats, horses and other companion animals.

North America as a single region. No country or sub-regional split is published.

It adds buyer intelligence, competitive and technology benchmarking, company profiles, commercial economics and go-to-market analysis.

Inquire Before Buying Request Free Sample Ask For Discount